Even though the cases above are the exception, and not the rule, most radiologists object to doing prophylactic filter insertions in patients who do not have thromboembolic diseases.
22.
A cohort study of approximately 1 million girls found no evidence supporting associations between exposure to quadrivalent human papillomavirus vaccine and autoimmune, neurological, and venous thromboembolic adverse events.
23.
Available clinical information for Bextra suggests there is no increased risk of cardiovascular thromboembolic events, or blood clots, in people treated for osteoarthritis and rheumatoid arthritis, Pfizer said.
24.
With low bleeding risk of dental procedures, it is recommended that NOAC medicine is still taken by patient as per normal, so as to avoid increase in the risk of thromboembolic event.
25.
On March 18, 2008, the European Medicines Agency granted marketing authorisation for Pradaxa for the prevention of thromboembolic disease following hip or knee replacement surgery and for non-valvular atrial fibrillation.
26.
Clinical trials have looked at riociguat as a new approach to treat two forms of pulmonary hypertension ( PH ) : chronic thromboembolic pulmonary hypertension ( CTEPH ) and pulmonary arterial hypertension ( PAH ).
27.
In August 2009 the Centers for Medicare and Medicaid Services concluded that " the available evidence does not demonstrate that pharmacogenomic testing of CYP2C9 or VKORC1 alleles to predict warfarin responsiveness improves health outcomes in thromboembolic events.
28.
For dental procedures with a higher risk of bleeding complications, the recommended practice is for patient to miss or delay a dose of their NOAC before such procedures so as to minimize the effect on thromboembolic risk.
29.
In chronic thromboembolic pulmonary hypertension ( WHO Group IV ), the blood vessels are blocked or narrowed with recurrent blood clots, and these clots can lead to release of substances that cause the blood vessels to constrict.
30.
It is a vitamin K antagonist that inhibits coagulation by blocking synthesis of coagulation factors II, VII, IX and X . It is used for the prophylaxis and treatment of thromboembolic disorders ( thrombosis / pulmonary embolism ).
